Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has provided an announcement.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced an extraordinary general meeting to be held on November 26, 2025, to discuss significant changes including the use of proceeds from its A share IPO and amendments to its Articles of Association. These changes could impact the company’s governance structure and operational strategies, potentially affecting its market positioning and stakeholder interests.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company is focused on developing and manufacturing pharmaceutical products, with a market focus on innovative drug development and biotechnology solutions.
Average Trading Volume: 6,079,766
Current Market Cap: HK$1.09B
Learn more about 1349 stock on TipRanks’ Stock Analysis page.